Key result
The combination of Amlexanox and Forskolin prevented left ventricular systolic dysfunction during chronic catecholamine stress by attenuating maladaptive myocardial hypertrophy, fibrosis, and inflammatory responses.
Why the study?
There are no well-defined treatment interventions targeted at both maladaptive myocardial hypertrophy and inflammation during chronic catecholamine stress to prevent pathological cardiac hypertrophy.
Does the combination of amlexanox and forskolin prevent pathological cardiac hypertrophy and left ventricular systolic dysfunction in a mouse model of chronic catecholamine stress?
Does the combination of amlexanox and forskolin prevent pathological cardiac hypertrophy and left ventricular systolic dysfunction in a mouse model of chronic catecholamine stress?
The combination of amlexanox and forskolin prevents isoproterenol-induced cardiomyopathy and left ventricular systolic dysfunction in mice by modulating GRK5 and ACs-cAMP pathways.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in catecholamine stress models; leaves open whether amlexanox-forskolin effects translate to human heart failure.
Chronic catecholamine stress (CCS) induces the occurrence of cardiomyopathy—pathological cardiac hypertrophy (PCH), which is characterized by left ventricular systolic dysfunction (LVSD). Recently, mounting evidence has implicated myocardial inflammation in the exacerbation of pathological cardiac remodeling. However, there are currently no well-defined treatment interventions or regimes targeted at both the attenuation of maladaptive myocardial hypertrophy and inflammation during CCS to prevent PCH. G protein-coupled receptor kinase 5 (GRK5) and adenylyl cyclases (ACs)-cAMP mediates both cardiac and inflammatory responses. Also, GRK5 and ACs are implicated in stress-induced LVSD. Herein, we aimed at preventing PCH during CCS via modulating adaptive cardiac and inflammatory responses by inhibiting GRK5 and/or stimulating ACs. Isoproterenol-induced cardiomyopathy (ICM) was modeled using 0.5 mg/100 g/day isoproterenol injections for 40 days. Alterations in cardiac and inflammatory responses were assessed from the myocardia. Similarities in the immunogenicity of cardiac troponin I (cTnI) and lipopolysaccharide under CCS were assessed, and Amlexanox (35 μM/ml) and/or Forskolin (10 μM/ml) were then employed in vitro to modulate adaptive inflammatory responses by inhibiting GRK5 or activating ACs-cAMP, respectively. Subsequently, Amlexanox (2.5 mg/100 g/day) and/or Forskolin (0.5 mg/100 g/day) were then translated into in vivo during CCS to modulate adaptive cardiac and inflammatory responses. The effects of Amlexanox and Forskolin on regulating myocardial systolic functions and inflammatory responses during CCS were ascertained afterward. PCH mice had excessive myocardial hypertrophy, fibrosis, and aggravated LVSD, which were accompanied by massive CD68+ inflammatory cell infiltrations. In vitro, Forskolin-AC/cAMP was effective than Amlexanox-GRK5 at downregulating proinflammatory responses during stress; nonetheless, Amlexanox and Forskolin combination demonstrated the most efficacy in modulating adaptive inflammatory responses. Individually, the translated Amlexanox and Forskolin treatment interventions were ineffective at subduing the pathological remodeling and sustaining cardiac function during CCS. However, their combination was potent at preventing LVSD during CCS by attenuating maladaptive myocardial hypertrophy, fibrosis, and inflammatory responses. The treatment intervention attained its potency mainly via Forskolin-ACs/cAMP-mediated modulation of cardiac and inflammatory responses, coupled with Amlexanox inhibition of GRK5 mediated maladaptive cascades. Taken together, our findings highlight the Amlexanox and Forskolin combination as a potential therapeutic intervention for preventing the occurrence of pathological cardiac hypertrophy during chronic stress.
No takes yet. Share an insight, caveat, or question.
Adzika et al. (2021) studied Isoproterenol-induced cardiomyopathy. Amlexanox and Forskolin combination vs. Vehicle / Isoproterenol alone was evaluated on Left ventricular systolic dysfunction, hypertrophy, and inflammatory responses. The combination of Amlexanox and Forskolin prevented left ventricular systolic dysfunction during chronic catecholamine stress by attenuating maladaptive myocardial hypertrophy, fibrosis, and inflammatory responses.
Synapse has enriched 10 related papers. Consider them for comparative context: